Thymosin Beta-4 (TB4)
Clinical TrialsThymosin Beta-4
The parent compound of TB-500. A naturally occurring 43 amino acid peptide involved in cell migration, wound healing, and tissue repair. More expensive and less stable than TB-500.
Dose
Varies by research indication, commonly discussed dosages range from 250 mcg to 1 mg
Route
SubQ injection, IV
Cycle
Commonly 4-8 weeks in research contexts, though duration can vary depending on the study objective
Storage
2°C to 8°C (refrigerator) for up to 2 years; -20°C for longer term storage
What is Thymosin Beta-4 (TB4)?
Thymosin Beta-4 (TB4) is a naturally occurring 43-amino acid peptide that plays a crucial role in various cellular processes, including cell migration, tissue repair, and wound healing. It is the parent compound of TB-500, a synthetic version often used in research. TB4 is involved in actin regulation, promoting its sequestration and enabling cell motility and plasticity. Research has explored its potential in cardiovascular repair, corneal healing, and skin wound healing due to its observed anti-inflammatory, angiogenic, and cell differentiation-promoting properties. While naturally abundant, synthetic TB4 is studied for its therapeutic applications, although it is typically more expensive and considered less stable than its derivative, TB-500, for research purposes.
Key Benefits
- Wound healing
- Cell migration promotion
- Heart protection
- Corneal healing research
- Stem cell activation
Mechanism of Action
- Regulates actin sequestration
- Promotes cell migration and differentiation
- Stimulates angiogenesis
- Anti-inflammatory effects
Best For
- Advanced healing research
- Cardiovascular research
- Ocular research
Body Systems
🐾 Griffin Says...
Molecular Information
Molecular weight
4963.4 g/mol
Length
43 amino acids
Type
Peptide
Amino acid sequence
Ac-SDKP-DMK-AEI-EKN-LPS-KET-IET-QEK-QAG-ES-NH2 (This is the sequence for the active fragment Ac-SDKP, the full sequence for TB4 is N-Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKAKNAVVN-C)
The provided sequence is for N-acetylated thymosin beta-4 (TB4). The commonly referenced 4-amino acid fragment Ac-SDKP is also often discussed as a highly active motif derived from TB4.
Research Indications
Wound Healing (Skin)
Extensively studied for promoting dermal repair, collagen deposition, and re-epithelialization in various wound models.
Corneal Healing
Research indicates potential for accelerating repair and reducing inflammation in corneal injuries and diseases.
Soft Tissue Repair
Investigated for its role in tendon, ligament, and muscle injury recovery due to its pro-regenerative properties.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Acute Wound Healing (e.g., skin injury) | 250 mcg - 1 mg | 2-3 times per week | Subcutaneous (SubQ) or directly to wound site (topical formulations are also discussed in research) |
| Cardiovascular Tissue Repair (e.g., post-MI models) | 500 mcg - 1 mg | 2 times per week | Subcutaneous (SubQ) or Intravenous (IV) |
| Corneal Epithelial Regeneration | 250 mcg - 500 mcg | 2-3 times per week | Subcutaneous (SubQ) or ocular drops (in specific research formulations) |
| General Tissue Regeneration and Anti-Inflammation | 500 mcg | 2 times per week | Subcutaneous (SubQ) |
| Investigation of Systemic Effects | 1 mg | 2 times per week | Intravenous (IV) |
Research protocols often involve consistent administration to maintain stable levels and facilitate sustained biological effects.
Peptide Interactions
- Use Caution
Corticosteroids
Corticosteroids have anti-inflammatory effects that could potentially oppose or modulate TB4's pro-healing and anti-inflammatory mechanisms. Specific research on this interaction is limited.
- Use Caution
Immunosuppressants
TB4 has some immune-modulating properties. Concurrent use with potent immunosuppressants should be monitored as it might alter immune responses.
- Synergistic
Growth Factors (e.g., EGF, FGF)
Research suggests TB4 may act synergistically with various growth factors to enhance wound healing and tissue regeneration, by promoting cell migration and angiogenesis.
- Compatible
Hyaluronic Acid
Often discussed in research for co-administration in regenerative medicine contexts, potentially providing a favorable microenvironment for TB4's actions.
- Monitor Combination
Anticoagulants/Antiplatelets
While not directly an anticoagulant, TB4's role in tissue repair and angiogenesis might indirectly impact coagulation pathways. Monitoring is advised, though direct interactions are not widely reported.
How to Reconstitute
- 1Gather materials: lyophilized TB4 vial, bacteriostatic water for injection (BWFI), sterile syringes (e.g., 1mL), sterile needles (e.g., 23-25 gauge for reconstitution, 27-30 gauge for injection), alcohol wipes.
- 2Clean vial tops: Wipe the rubber stopper of the TB4 vial and the BWFI vial with separate alcohol wipes and allow to air dry.
- 3Draw diluent: Using a sterile syringe, draw the desired amount of BWFI (e.g., 1 mL for a 5mg vial) to achieve the target concentration. A common reconstitution ratio is 1ml per 5mg vial.
- 4Inject diluent: Slowly inject the BWFI into the TB4 vial, directing the stream down the side of the vial to avoid direct spraying onto the powder.
- 5Gentle mixing: Do not shake the vial. Gently swirl the vial to allow the powder to dissolve completely. This may take a few minutes. Ensure no visible particulate matter remains.
- 6Storage: Once reconstituted, store the vial in the refrigerator at 2°C to 8°C. Consult specific product guidelines for stability duration, typically 7-14 days.
Aseptic technique is critical during reconstitution to maintain sterility.
What to Expect
- Weeks 1-2: Initial systemic distribution and potential for subtle improvements in general well-being or initiation of cellular processes related to the research objective.
- Weeks 3-4: More noticeable effects may begin to manifest, such as enhanced tissue recovery or early signs of improved functionality depending on the research area.
- Weeks 5-8: Continued progression of therapeutic effects, with potential for significant improvements in wound healing, tissue regeneration, or cardiovascular parameters as observed in research studies.
- Beyond 8 weeks: Research protocols might extend or cycle administration based on ongoing assessment of efficacy and safety, particularly for chronic conditions or long-term regenerative studies.
Side Effects & Safety
| Effect | Frequency | Severity |
|---|---|---|
| Fatigue | Uncommon | Mild |
| Injection site irritation | Common | Mild |
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.